Family history of prostate cancer does not affect some treatment outcomes

	Tweet

In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.

“This information is relevant for both physicians and patients with new diagnoses as they embark on complex treatment decisions,” Christopher A. Peters, M.D., lead author of the study and a radiation oncologist at Northeast Radiation Oncology Center in Dunmore, Pa. (chief resident at Mount Sinai School of Medicine at the time of the study), said. “Now patients with a family history of prostate cancer can be confident that they have the same outcomes as patients with sporadic disease, regardless of the treatment modality they chose.”

According to the American Cancer Society, prostate cancer is the most common cancer in men behind skin cancer. Many patients diagnosed with prostate cancer have some type of family history of the disease and men with a family history do have an increased risk of developing the disease, but there is conflicting data on how family history impacts treatment outcomes. 

In the study, researchers at the Departments of Radiation Oncology and Urology at the Mount Sinai School of Medicine in New York sought to determine if having a familial history of prostate cancer, which is defined as a clustering of prostate cancer cases within a family, had an impact on the prognosis of men treated with brachytherapy for clinically localized prostate cancer patients.

Researchers followed 1,738 prostate cancer patients, of which 187 had a family history of prostate cancer in a first-degree relative, for a median follow-up time of 60 months. They found that in the low-, intermediate- and high-risk groups, a family history of prostate cancer had little to no prognostic significance in men treated with brachytherapy. Previous studies done with prostate cancer patients receiving external beam radiation therapy or radical prostatectomy had similar findings.

###

ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to improving patient care through education, clinical practice, advancement of science and advocacy.

Contact: Beth Bukata

703-839-7332
American Society for Therapeutic Radiology and Oncology

RELATED STORIES:
Infertility linked to prostate cancer   New data show benefit of finasteride in preventing prostate cancer   PSA test alone not an ideal predictor of prostate cancer   Long-term hormone therapy best for prostate cancer   Dutasteride useful for enlarged prostate   Too many old men get prostate cancer tests: study   New Approach for Treating Recurrent Prostate Cancer on the Horizon   Does age matter in selection of treatment for men with early-stage prostate cancer?   PSA Predicts Treatment Success in Advanced Prostate Cancer   Not all cancer patients improve lifestyle   Soft drink consumption may increase risk of pancreatic cancer   Immunologic tests detect hidden prostate cancer   Swiss study finds income affects prostate cancer patients’ survival   Gene Linked to Aggressive Prostate Cancer   Most prostate cancer patients opt for surgery   No Evidence That Widely Prescribed Statins Protect Against Prostate Cancer   Pros and cons with “easier” prostate cancer surgery   Low-grade prostate cancer may not require aggressive treatment   Study shows further benefits of noscapine for prostate cancer   Prostate cancer patients disease free after 5 years likely to be disease free after 10 years   Urine test improves prostate diagnosis   Mushroom extract may boost prostate cancer drug

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]